Nuvaxovid is similar to flu jab and may have reduced side-effects, which could persuade vaccine holdouts
The Covid-19 vaccine developed by Novavax has been approved by the UK regulator for use in people over the age of 18.
The vaccine will not be immediately widely available as its use as part of the UK’s vaccination programme will be considered by the independent Joint Committee on Vaccination and Immunisation.
